Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial (vol 395, pg 1496, 2020)

首页> 外文期刊>The Lancet >Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial (vol 395, pg 1496, 2020)

【24h】

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial (vol 395, pg 1496, 2020)

机译：Secukinumab与Adalimumab用于治疗活性银屑病关节炎（超过）：双盲，平行组，随机，主动控制，第3B期试验（Vol 395，PG 1496,2020）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Lancet》 |2020年第10238期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献

1. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial (vol 395, pg 1496, 2020) [J] . The Lancet . 2020,第10238期

机译：Secukinumab与Adalimumab用于治疗活性银屑病关节炎（超过）：双盲，平行组，随机，主动控制，第3B期试验（Vol 395，PG 1496,2020）
2. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period [J] . Emery Paul, Burmester Gerd R., Bykerk Vivian P., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2015,第1期

机译：在早期类风湿关节炎中评估使用abatacept的无药缓解：3b期，多中心，随机，主动对照的AVERT研究为期24个月，为期12个月，双盲治疗
3. Comparison of the efficacy and safety of CELBESTA? versus CELEBREX? in patients with rheumatoid arthritis: a 6-week, multicenter, double-blind, double-dummy, active-controlled, randomized, parallel-group, non-inferiority phase 4 clinical trial [J] . Hyun-Sook Kim, Won-Ho Choi, Bo Young Kim, Journal of International Medical Research . 2020,第6期

机译：Celbesta的疗效和安全性比较？与Celebrex？在类风湿性关节炎的患者中：6周，多中心，双盲，双静脉，有效控制，随机，并行组，非劣级阶段4临床试验
4. Extended report: Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised double-blind parallel-group phase III trial [O] . Gerd R Burmester, Yong Lin, Rahul Patel, -1

机译：扩展报告：sarilumab单药和阿达木单抗单药治疗活动性类风湿关节炎（MONARCH）的疗效和安全性：一项随机双盲平行组III期临床试验
5. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1 [O] . Mease, Philip J., van der Heijde, Désirée, Ritchlin, Christopher T., 2017

机译：Ixekizumab，一种白介素17A特异性单克隆抗体，用于治疗患有生物学性初发性银屑病关节炎的初生生物患者：III期24周随机，双盲，安慰剂对照和活性（阿达木单抗）对照期的结果试用SPIRIT-P1

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial (vol 395, pg 1496, 2020)

著录项

相似文献

相关主题

期刊订阅